Sindrome di Noonan

Translated title of the contribution: Noonan syndrome

Giuseppe Zampino, Chiara Leoni, Marco Tartaglia

Research output: Contribution to journalArticle

Abstract

Noonan Syndrome is a clinically and genetically heterogeneous condition, with autosomal dominant inheritance, characterized by dinstintive facial features, congenital heart defects, postnatal growth retardation (weight and height), variable psycomotor delay, and other comorbidities (involvement of visual, lymphatic, coagulative, genital, skeletal, ectodermic and rarely hematopoietic system). Its estimated prevalence is 1:1,000-1:2,500 live births. Noonan syndrome is caused by mutations in genes coding for proteins with role in RAS-MAPK signal transduction pathway. So far, the identified disease genes (PTPN11, SOS1, KRAS, NRAS, RAF1 and BRAF) allow to confirm the diagnosis molecularly in approximately 75% of affected individuals.

Original languageItalian
Pages (from-to)120-123
Number of pages4
JournalArea Pediatrica
Volume12
Issue number3
Publication statusPublished - Jun 2011

Fingerprint

Noonan Syndrome
Hematopoietic System
Congenital Heart Defects
Live Birth
Comorbidity
Signal Transduction
Weights and Measures
Mutation
Growth
Genes
Proteins

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Zampino, G., Leoni, C., & Tartaglia, M. (2011). Sindrome di Noonan. Area Pediatrica, 12(3), 120-123.

Sindrome di Noonan. / Zampino, Giuseppe; Leoni, Chiara; Tartaglia, Marco.

In: Area Pediatrica, Vol. 12, No. 3, 06.2011, p. 120-123.

Research output: Contribution to journalArticle

Zampino, G, Leoni, C & Tartaglia, M 2011, 'Sindrome di Noonan', Area Pediatrica, vol. 12, no. 3, pp. 120-123.
Zampino G, Leoni C, Tartaglia M. Sindrome di Noonan. Area Pediatrica. 2011 Jun;12(3):120-123.
Zampino, Giuseppe ; Leoni, Chiara ; Tartaglia, Marco. / Sindrome di Noonan. In: Area Pediatrica. 2011 ; Vol. 12, No. 3. pp. 120-123.
@article{4c708a48788b4771a17411d437d7f32f,
title = "Sindrome di Noonan",
abstract = "Noonan Syndrome is a clinically and genetically heterogeneous condition, with autosomal dominant inheritance, characterized by dinstintive facial features, congenital heart defects, postnatal growth retardation (weight and height), variable psycomotor delay, and other comorbidities (involvement of visual, lymphatic, coagulative, genital, skeletal, ectodermic and rarely hematopoietic system). Its estimated prevalence is 1:1,000-1:2,500 live births. Noonan syndrome is caused by mutations in genes coding for proteins with role in RAS-MAPK signal transduction pathway. So far, the identified disease genes (PTPN11, SOS1, KRAS, NRAS, RAF1 and BRAF) allow to confirm the diagnosis molecularly in approximately 75{\%} of affected individuals.",
keywords = "Noonan syndrome, Poor growth, Pulmonary valve stenosis",
author = "Giuseppe Zampino and Chiara Leoni and Marco Tartaglia",
year = "2011",
month = "6",
language = "Italian",
volume = "12",
pages = "120--123",
journal = "Area Pediatrica",
issn = "1591-0075",
publisher = "Masson SpA",
number = "3",

}

TY - JOUR

T1 - Sindrome di Noonan

AU - Zampino, Giuseppe

AU - Leoni, Chiara

AU - Tartaglia, Marco

PY - 2011/6

Y1 - 2011/6

N2 - Noonan Syndrome is a clinically and genetically heterogeneous condition, with autosomal dominant inheritance, characterized by dinstintive facial features, congenital heart defects, postnatal growth retardation (weight and height), variable psycomotor delay, and other comorbidities (involvement of visual, lymphatic, coagulative, genital, skeletal, ectodermic and rarely hematopoietic system). Its estimated prevalence is 1:1,000-1:2,500 live births. Noonan syndrome is caused by mutations in genes coding for proteins with role in RAS-MAPK signal transduction pathway. So far, the identified disease genes (PTPN11, SOS1, KRAS, NRAS, RAF1 and BRAF) allow to confirm the diagnosis molecularly in approximately 75% of affected individuals.

AB - Noonan Syndrome is a clinically and genetically heterogeneous condition, with autosomal dominant inheritance, characterized by dinstintive facial features, congenital heart defects, postnatal growth retardation (weight and height), variable psycomotor delay, and other comorbidities (involvement of visual, lymphatic, coagulative, genital, skeletal, ectodermic and rarely hematopoietic system). Its estimated prevalence is 1:1,000-1:2,500 live births. Noonan syndrome is caused by mutations in genes coding for proteins with role in RAS-MAPK signal transduction pathway. So far, the identified disease genes (PTPN11, SOS1, KRAS, NRAS, RAF1 and BRAF) allow to confirm the diagnosis molecularly in approximately 75% of affected individuals.

KW - Noonan syndrome

KW - Poor growth

KW - Pulmonary valve stenosis

UR - http://www.scopus.com/inward/record.url?scp=79959900476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959900476&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:79959900476

VL - 12

SP - 120

EP - 123

JO - Area Pediatrica

JF - Area Pediatrica

SN - 1591-0075

IS - 3

ER -